Highlights of weekly biotech stock moves

Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) lost $1.10 to $14 last week after announcing EMA accepted for review an MAA for lomitapide to treat homozygous familial hypercholesterolemia (HoFH).

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) gained $0.31 to $15.72 last week even though FDA's Oncologic Drugs Advisory Committee voted 13-1 that Taltorvic ridaforolimus from partner Merck & Co. Inc. (NYSE:MRK) did not demonstrate a favorable benefit-risk profile as a maintenance therapy for metastatic soft tissue or bone sarcoma patients with stable disease following chemotherapy. The PDUFA date is June 5 (see "Defining Meaningful," A12)...